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Objective. Patients with systemic sclerosis–
associated interstitial lung disease (SSc-ILD) are
thought to have the greatest decline in lung function
(forced vital capacity [FVC] % predicted) in the early
years after disease onset. The aim of this study was to
assess the natural history of the decline in FVC %
predicted in patients receiving placebo in the Sclero-
derma Lung Study and to evaluate possible factors for
cohort enrichment in future therapeutic trials.
Methods. Patients randomized to receive placebo
(n  79) were divided into 3 groups based on the
duration of SSc (0–2 years, 2–4 years, and >4 years).
Descriptive statistics and a mixed-effects model were
used to analyze the rate of decline in the FVC %
predicted over a 1-year period. Additional analyses
stratified according to the severity of fibrosis on high-
resolution computed tomography (HRCT) were per-
formed, and interactions between disease severity and
disease duration were explored.
Results. The mean  SD decline in the unad-
justed FVC % predicted during the 1-year period was
4.2  12.8%. At baseline, 28.5%, 43.0%, and 28.5% of
patients were in the groups with disease durations of
0–2 years, 2–4 years, and >4 years, respectively. The
rate of decline in the FVC % predicted was not signifi-
cantly different across the 3 disease groups (P  0.85).
When stratified by baseline fibrosis on HRCT, the rate
of decline in the FVC % predicted was statistically
significantly greater in the group with severe fibrosis
(mean annualized decline in the FVC % predicted 7.2%
versus 2.7% in the groups with no or moderate fibrosis;
P  0.008). The decline observed in the group with
severe fibrosis was most pronounced in those with a
relatively short disease duration (0–2 years; annualized
decline 7.0%).
Conclusion. Among patients with SSc-ILD in the
Scleroderma Lung Study, the rates of progression of
lung disease were similar irrespective of disease dura-
tion. The baseline HRCT fibrosis score is a predictor of
a future decline in the FVC % predicted in the absence
of effective treatment.
Pulmonary disease is the leading cause of hospi-
talization and mortality in patients with systemic sclero-
sis (SSc) (1). Approximately 40% of patients with SSc
develop moderate to severe restrictive lung disease (2).
Longitudinal cohorts have provided important informa-
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tion on the natural history of lung disease in SSc. Most
of the decline in pulmonary function occurs during the
first 3–4 years after the onset of non-Raynaud’s symp-
toms of SSc (2,3), and the course of pulmonary involve-
ment is indolent after that. However, there is intraindi-
vidual variability in the changes in pulmonary physiology
tests over time in patients with SSc. In addition, recent
data suggest that the presence of moderate-to-severe
fibrosis at baseline predicts poor survival in patients with
SSc-associated interstitial lung disease (SSc-ILD) (4).
Results from the recently concluded Scleroderma
Lung Study (SLS-I) (5), a randomized, placebo-
controlled clinical trial, showed that a regimen of oral
cyclophosphamide administered daily for 12 months was
better than placebo for stabilizing lung function as
measured by the forced vital capacity (FVC) % pre-
dicted and improving health-related quality of life (6,7)
in patients with SSc-ILD during the treatment period.
This large study recruited 158 patients with SSc-ILD, of
whom 79 received placebo for a period of 1 year. Based
on previous studies (2,8), the SLS-I investigators hypoth-
esized a 9% annualized decline in the FVC % predicted
(5). However, the study noted a decline of 2.6% over the
1-year treatment period in the patients assigned to
receive placebo. Therefore, we sought to evaluate the
variables associated with a greater decline in the FVC %
predicted, because such characteristics could be useful
for cohort enrichment in future therapeutic trials in
SSc-ILD.
PATIENTS AND METHODS
Subjects. The study group comprised patients with
SSc who participated in SLS-I and were considered to have
SSc-ILD as defined by evidence of alveolitis on bronchoalveo-
lar lavage (neutrophils 3%, eosinophils 2%) and/or
ground-glass opacification on high-resolution computed tomo-
graphy (HRCT). Other inclusion criteria were onset of the first
non–Raynaud’s phenomenon manifestation 7 years prior to
entry (based on data described by Steen et al [2]), FVC
between 45% and 85% of the predicted value, and at least
grade 2 dyspnea according to the baseline dyspnea index
(BDI) described by Mahler et al (e.g., shortness of breath
when climbing 2 flight of stairs) (9,10). Further details of
the inclusion and exclusion criteria have been described pre-
viously (5).
Pulmonary function tests. Baseline measures of FVC,
total lung capacity, and single-breath diffusing capacity for
carbon monoxide (DLCO) were obtained at the time of study
entry and then every 3 months for the duration of the study.
Pulmonary function tests were performed on study-certified
equipment in accordance with recommended standards
(11,12), and the quality of the tests was carefully monitored by
centralized overreading, as previously described (5). All spiro-
metric and DLCO procedures had to be carried out on equip-
ment that met the performance standards of the American
Thoracic Society. All tests were carried out in University-based
pulmonary function laboratories, and all sites were visited by
the Director of the Pulmonary Function Quality Control Core
for SLS-I (DPT). Moreover, as part of the overall pulmonary
function quality control process, printouts of calibration curves
and of all numerical and graphic results were submitted on a
regular basis to the Pulmonary Function Quality Control Core
for quality assessment. The overall quality of the test results,
while varying somewhat from site to site in this 13-center study,
was judged to range from satisfactory to excellent.
High-resolution computed tomography. HRCT scans
were obtained with the subject in the prone position, without
contrast, from the lung apices to the bases (13). Two indepen-
dent radiologists who were blinded to the treatment assign-
ment (cyclophosphamide or placebo for 12 months) carried
out the scoring based on semiquantitative visual assessment.
Lung images were divided into 3 zones for each lung. The
upper lung zone extended from the lung apices to the aortic
arch, the middle lung zone consisted of the area from the aortic
arch to the inferior pulmonary veins, and the lower lung zone
was assigned to the area from the inferior pulmonary veins to
the diaphragm. Each of the 6 zones (except for 20 patients who
were not scanned in the upper lung zone) from the right and
left lungs was scored for ground-glass opacification (opacity
through which normal lung markings could be seen), fibrosis
(reticular opacity, traction bronchiectasis, and/or bronchiolec-
tasis), and honeycomb cysts (14). Because SSc-ILD predomi-
nantly affects the lower lung zones, we believed that an average
score across all lung zones would dilute the effect of the most
severely affected zones. Therefore, we used the score from the
zone with the worst extent of abnormality (maximum score) in
our analyses. In all patients (except for 1), the maximum
fibrosis score at baseline was represented by the lower lung
zones. Therefore, although the lung apices were not scanned in
14% of the patients, it is unlikely that we missed zones with the
true maximum score in these patients. Scoring for the extent of
involvement in each lung zone was as follows: 0  absence of
any pulmonary abnormality, 1  1–25%, 2  26–50%, 3 
51–75%, and 4  76–100%.
Autoantibodies. Autoantibody data were available for
55 patients and included anti–Scl-70, anti–RNA polymerase
III, and anticentromere antibodies, which were analyzed by
enzyme-linked immunosorbent assays from Alpco Diagnostics
(Scl-70 and anticentromere) and MBL International (anti–
RNA polymerase III).
Statistical analysis. Based on the previous analysis by
Steen and colleagues (2), we divided the patients in the
placebo group into 3 subgroups based on the duration of SSc
prior to study entry, as follows: 0–2 years (group A), 2–4 years
(group B), and 4 years (group C). Disease duration was
defined as the duration from the onset of the first non-
Raynaud’s sign or symptom attributed to SSc as determined by
direct interview of participating patients during screening and
was captured in the case report form. The outcomes of interest
were the annual rates of decline in the FVC and DLCO %
predicted. Due to baseline differences in physiologic measures
in the 3 disease-duration groups, the outcomes were examined
as the change in the FVC or DLCO % predicted over the 1-year
period divided by the baseline FVC or DLCO % predicted.
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Because our goal was to evaluate variables associated
with a greater decline in FVC for cohort enrichment in future
therapeutic trials, we examined the influence on the observed
rate of decline in patients assigned to placebo of prespecified
variables that were previously shown to be associated with a
decline in the FVC % predicted or mortality in SLS-I and
other cohorts (4). Summary statistics for baseline demographic
and clinical data among the 3 disease-duration groups were
generated. Analysis of variance was used to compare continu-
ous variables among the 3 groups, and Fisher’s exact test or the
chi-square test was used to compare categorical variables.
Two-year data were not included due to discontinuations
during the second year.
We used a linear mixed-effects model to evaluate the
association between the outcome variables (rate of decline in
the FVC and DLCO % predicted) and covariates with a
random intercept to account for within-subject correlation of
the outcome variables across multiple visits. First, we gener-
ated 3 models to assess the associations between the maximum
scores for HRCT fibrosis, ground-glass opacification, and
honeycombing at baseline on the rates of decline in the FVC
and DLCO % predicted, including variables of time, disease
duration, and interactions among time, disease duration, and
HRCT scores. If there was a significant association, we used
linear mixed-effects models to assess the relationships between
primary outcome measures (rate of decline in the FVC and
DLCO % predicted) and the following covariates: disease
duration, maximum HRCT scores at baseline (fibrosis, honey-
combing, ground-glass opacification), age, sex, baseline BDI
scores, autoantibody status (anti–Scl-70 versus anti–RNA poly-
merase III versus anticentromere and others), smoking status,
and the modified Rodnan skin thickness score. We also
performed sensitivity analyses after reclassifying disease dura-
tion by including Raynaud’s phenomenon in the definition of
the first sign or symptom of SSc.
All analyses were performed using SAS software. P
values less than 0.05 were considered significant. Because this
was an exploratory analysis, we did not account for multiple
comparisons.
RESULTS
Seventy-nine of 158 eligible patients were ran-
domly assigned to receive placebo; 77 of these patients
had a known baseline disease duration and were in-
cluded in the current analysis. Of these 77 patients, 66
completed the 12-month study visit; 55 of these 66
patients completed all clinic visits, and the remaining 11
patients had withdrawn from randomized treatment or
had been considered treatment failures at some time
during the treatment year but returned to complete the
12-month study visit. At baseline, 22 patients (28.5%)
were in group A, 33 patients (43.0%) were in group B,
and 22 patients (28.5%) were in group C.
Table 1 presents the baseline characteristics of
patients in the placebo group according to the 3 catego-






years (n  22)
Group B, disease
duration 2–4
years (n  33)
Group C, disease
duration 4
years (n  22)
Age, years 48.3  12.5 56.2  12.4 46.4  11.9 43.4  10.1
Female sex, no. (%) 48.0 (62.3) 12.0 (54.6) 18.0 (54.6) 18.0 (81.8)
White race, no. (%) 51.0 (66.2) 15.0 (68.2) 22.0 (66.7) 14.0 (63.6)
Type of SSc, no. (%)
Limited 32 (41.6) 8.0 (36.4) 16.0 (48.5) 8.0 (36.4)
Diffuse 45.0 (58.4) 14.0 (63.6) 17.0 (51.5) 14.0 (63.6)
Disease duration, years 3.2  1.9 1.1  0.6 3.0  0.6 5.7  0.7
Antibody positivity, no. (%)†
Anti–Scl-70 19 (35) 1 (8) 7 (28) 11 (65)
Anti–RNAP III/anticentromere 5 (9) 0 (0) 4 (16) 1 (6)
Others 31 (56) 12 (92) 14 (56) 5 (29)
FVC, % predicted 68.19  12.9 65.5  13.4 68.2  13.9 70.8  10.7
DLCO, % predicted 46.8  13.9 44.9  13.9 46.1  12.9 49.8  15.6
Modified Rodnan skin thickness score (range 0–51) 14.2  10.8 16.8  12.1 13.3  10.5 12.9  9.1
Mahler’s BDI focal score (range 0–12) 5.7  1.9 6.8  2.1 5.2  1.8 5.4  1.8
HAQ disability index (range 0–3) 0.70  0.70 0.9  0.7 0.7  0.7 0.6  0.6
SF-36 PCS 34.5  10.8 30.4  11.9 35.5  9.8 37.0  10.5
SF-36 MCS 50.8  10.5 48.3  10.7 52.9  8.5 50.2  12.9
HRCT-defined disease extent
Maximum fibrosis score (range 0–4) 2.0  1.1 2.1  1.2 2.0  1.0 2.0  1.0
Maximum honeycombing (range 0–4) 0.5  0.5 0.5  0.5 0.5  0.6 0.4  0.5
Maximum ground-glass opacification (range 0–4) 0.7  0.8 0.6  0.7 0.8  0.9 0.7  0.6
* Except where indicated otherwise, values are the mean  SD. Disease duration was defined as the time from the onset of the first non–Raynaud’s
phenomenon manifestation. SSc  systemic sclerosis; anti–RNAP III  anti–RNA polymerase III; FVC  forced vital capacity; DLCO  diffusing
capacity for carbon monoxide; BDI  baseline dyspnea index; HAQ  Health Assessment Questionnaire; SF-36  Short Form 36; PCS  physical
component summary; MCS  mental component summary; HRCT  high-resolution computed tomography.
† Antibody data were available for only 55 patients.
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ries of disease duration. Patients in group A were
significantly older at baseline compared with patients in
the other 2 groups (mean age 56.2 years for group A
versus 46.4 years and 43.4 years for patients in groups B
and C, respectively), there was a trend toward a higher
proportion of female patients in group C, and the BDI
focal scores were significantly higher in group A than in
groups B and C. Autoantibody data were available in 55
patients. Of these, 19 patients (35%) had anti–Scl-70
antibodies, 5 patients (9%) were positive for anti-RNA
polymerase III and anticentromere antibodies, and 31
(56%) had other antibodies that were not characterized
(Table 1). Patients in group A had slightly lower baseline
FVC and DLCO % predicted values compared with the
other 2 groups, but these differences were not statisti-
cally significant (P  0.6 for both the FVC and DLCO %
predicted). No significant differences in health-related
quality of life measures or in the HRCT-defined disease
extent were observed across the 3 groups.
Rate of decline in the FVC and DLCO % pre-
dicted, stratified by disease-duration groups. For all
groups considered together, the mean  SD decline in
the unadjusted FVC % predicted was 4.2  12.8%
(Table 2), and the mean  SD decline in the unadjusted
DLCO % predicted was 8.2  18.6%. The change in the
FVC % predicted over 12 months was not correlated
with the baseline FVC % predicted (r  0.08, P 
0.54). No significant differences in the unadjusted rates
of decline in the FVC % predicted were observed across
the 3 groups (P  0.85) (Figure 1A and Table 2). No
between-group differences were observed in the rate of
decline in the FVC % predicted adjusted for the base-
line FVC % predicted (Figure 1B). For DLCO % pre-
dicted values, group A had a greater mean  SD decline
(17.9  26.3%) over 12 months compared with groups B
and C (P  0.03) (additional information is available
from the corresponding author).
Rate of decline in the FVC and DLCO % pre-
dicted, stratified by maximum HRCT scores at baseline.
We explored the impact of maximum HRCT scores for
fibrosis, ground-glass opacification, and honeycombing
at baseline on the rate of decline in the FVC and DLCO
% predicted. The cut-off HRCT values for comparison
were based on the distribution of the baseline HRCT
variables. No differences in the rates of decline were
observed among patients stratified according to the
severity of ground-glass opacification or honeycombing
(P not significant) (Table 2). In contrast, when patients
were stratified according to the maximum HRCT fibro-
sis score, those with severe fibrosis showed a greater
mean  SD decline in the FVC % predicted (7.2 
11.8%) compared with the group with no or moderate
fibrosis (2.7  12.8%; P  0.008) (Table 2 and Figure 2).
The differences in the rates of decline in the DLCO %
predicted between patients with severe fibrosis and
those with no or moderate fibrosis were not significant
(Figure 3) (additional information is available from the
corresponding author).
We assessed the impact of disease duration on
Figure 1. A, Decline in the unadjusted forced vital capacity (FVC) %
predicted over 12 months, according to disease duration (●  0–2
years; Œ  2–4 years;   4 years). B, Rate of decline in the FVC %
predicted adjusted for the baseline FVC % predicted. Values shown
above the x-axis represent the numbers of patients corresponding to
the data points for the given months.








0–2 17 4.4  18.8 0.85
2–4 29 4.4  10.1
4 18 3.5  10.1
HRCT fibrosis score
0–2 40 2.7  12.8 0.008
3–4 25 7.2  11.8
HRCT ground-glass opacification score
0–1 55 4.9  13.0 0.61
2–3 10 1.8  9.8
HRCT honeycombing score
0 38 3.8  14.5 0.96
1 27 5.3  9.2
Autoantibody positivity
Anti–Scl-70 17 5.2  9.1 0.88
Anti–RNAP III/anticentromere 5 6.9  11.5
Others 26 4.4  11.8
Overall 66 4.2  12.8
* Except where indicated otherwise, values are the mean  SD.
FVC  forced vital capacity; HRCT  high-resolution computed
tomography; anti–RNAP III  anti–RNA polymerase III.
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the decline in the FVC % predicted according to the
HRCT fibrosis category. Patients in group A (disease
duration 0–2 years) with HRCT fibrosis scores of 3–4
had a greater decline in the FVC % predicted (change of
7.04 [8.70%]) compared with group A patients with
HRCT fibrosis scores of 0–2 (change of 0.94 [12.24%])
(P  0.03). In contrast, among patients in group B
(disease duration 2–4 years) and group C (disease
duration 4 years), no significant differences in the rate
of decline in the FVC % predicted according to the
fibrosis scores were observed (Figure 4). In the linear
mixed-effects model, an HRCT fibrosis score of 3
was associated with a significant decline in the FVC %
predicted (P  0.004) after adjusting for covariates (ad-
ditional information is available from the corresponding
author). The models that included different degrees of
ground-glass opacification and honeycombing did not
show any significant association with the decline in the
FVC % predicted, irrespective of disease duration.
We further assessed the statistical interaction
between the HRCT fibrosis score and disease duration
in the 3 patient groups. Patients in group A had a sig-
nificant interaction between fibrosis (fibrosis score 3)
and the number of months of treatment (P  0.03),
demonstrating that patients with an HRCT fibrosis score
of 3 and a disease duration of 0–2 years had an
increased decline in the FVC % predicted over 12
months of treatment compared with those with lesser
degrees of fibrosis. In group A, the annualized rates of
decline were 7.0% in patients with a fibrosis score of
3–4 and 0.9% in patients with a fibrosis score of 0–2.
This interaction between fibrosis and months of treat-
ment was not significant for other disease durations.
No association was observed between HRCT scores
(fibrosis, ground-glass opacification, and honeycombing)
and the DLCO % predicted for any category of disease
duration.
We reclassified disease duration by including
Raynaud’s phenomenon in the definition of the first SSc
sign or symptom. The median (interquartile range
[IQR]) disease duration was 1.6 years (IQR 1.2–1.9) for
Figure 4. Rate of decline in forced vital capacity (FVC) % pre-
dicted adjusted for the baseline FVC % predicted, according to
high-resolution computed tomography–defined maximum fibrosis
scores (●  0–2; Œ  3–4) in the 3 disease-duration groups. Values
above the x-axis represent the numbers of patients corresponding to
the data points for the given months.
Figure 2. A, Decline in forced vital capacity (FVC) % predicted,
according to high-resolution computed tomography–defined maxi-
mum fibrosis scores (●  0–2; Œ  3–4). B, Rate of decline in the FVC
% predicted adjusted for the baseline FVC % predicted. Values above
the x-axis represent the numbers of patients corresponding to the data
points for the given months.
Figure 3. A, Decline in the diffusing capacity for carbon monoxide
(DLCO) % predicted values over 12 months, according to high-
resolution computed tomography–defined maximum fibrosis scores
(●  0–2; Œ  3–4). B, Rate of decline in DLCO % predicted adjusted
for the baseline DLCO % predicted. Values above the x-axis represent
the numbers of patients corresponding to the data points for the given
months.
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group A, 2.5 years (IQR 2.5–4.4) for group B, and
6.7 years (IQR 5.5–8.2) for group C. When disease
duration was reclassified from the date at which Ray-
naud’s phenomenon was identified to determine the
onset of SSc, no differences were observed when com-
pared with use of the date of the first non-Raynaud’s
sign or symptom to define onset of SSc.
Rate of decline in the FVC and DLCO % pre-
dicted, stratified by the presence of autoantibodies. The
rates of decline in the FVC % predicted were similar in
patients with anti–Scl-70 autoantibodies versus those
with other autoantibodies (P  0.88) (Table 2). Similar
results were observed for the DLCO % predicted (addi-
tional information is available from the corresponding
author).
DISCUSSION
SLS-I was the first randomized controlled clinical
trial in patients with SSc-ILD to demonstrate the effi-
cacy of a pharmacologic intervention (5). Because daily
administration of oral cyclophosphamide for 12 months
affected the change in the FVC % predicted over 1 year,
the placebo group was selected for analysis to avoid
confounding by active treatment. The placebo group
comprised a large number of patients, providing a
unique opportunity to assess the natural history of
SSc-ILD over a 1-year period.
In the current analysis, we showed that the pla-
cebo group had a decline in unadjusted FVC and DLCO
% predicted values (4.2% and 8.2%, respectively) over a
period of 12 months. The unadjusted rates of decline in
the FVC and DLCO % predicted were similar across the
categories of disease duration (0–2 years, 2–4 years, and
4 years). A greater extent of maximum fibrosis on
HRCT at baseline was associated with a greater decline
in the FVC % predicted, and this effect on the FVC %
predicted was most evident during the first 2 years after
disease onset. The reason why a greater extent of fibrosis
at baseline predisposes to a greater rate of decline in a
physiologic indicator of disease severity in patients with
evidence of ILD is not clear. A possible explanation for
these findings may be that a greater extent of fibrosis at
baseline in such patients might represent more rapid
progression from inflammation to lung fibrosis prior to
study entry that continues during the ensuing year, as
reflected by a greater rate of decline in the FVC %
predicted over this period of time.
Previous published data on the decline in lung
function come from a large observational cohort at the
University of Pittsburgh. Steen et al (2) demonstrated
that the major decline in FVC occurred within the first
4–6 years of SSc. Patients in whom severe restrictive
disease developed (FVC 50% of predicted) had lost
32% of the remaining FVC each year for the first 2
years, 12% of the remaining FVC for each of the next 2
years, and 3% of the remaining FVC for each of the
following 2 years. In another observational study from
Greece, Plastiras and colleagues retrospectively ana-
lyzed patients with SSc (3) and observed that baseline
FVC % predicted values measured in 60 patients within
the first 3 years after disease onset predicted the subse-
quent rate of change in pulmonary function. Neither
Steen et al (2) nor Plastiras et al (3) performed HRCT
or bronchoalveolar lavage in their cohorts.
In a nonrandomized treatment study of patients
with SSc-ILD and evidence of alveolitis on bronchoal-
veolar lavage, White et al (8) retrospectively compared
patients who were treated with oral cyclophosphamide
with those who refused therapy. Oral cyclophosphamide
was administered for a median of 10.8 months, and the
investigators noted a 4.3% improvement in the FVC %
predicted among treated patients (compared with a
7.1% decline in those who refused treatment with cyclo-
phosphamide) (8).
Based on results of the 2 observational studies
and the study by White and colleagues (8), SLS-I was
designed to capture patients with both a relatively short
disease duration (defined as 7 years from the onset of
the first non–Raynaud’s phenomenon manifestation)
and evidence of presumed active ILD (defined by bron-
choalveolar lavage and/or HRCT), with the assumption
that these patients would have a greater decline in the
FVC % predicted over a period of 1 year. However, in
SLS-I, the rate of decline in the FVC % predicted was
only 4.2% over a 12-month period and did not vary
across the 3 disease-duration groups.
We suspect that the lack of any demonstrable
effect of disease duration on the rate of decline in our
patient population might be attributable to inherent
differences in patients enrolled in a randomized con-
trolled trial versus patients followed up in observational
studies. It is likely that patients with moderate-to-severe
disease and rapidly declining lung physiology were likely
underrepresented in SLS-I; patients with less extensive
disease may be selectively enrolled in a placebo-
controlled study, while those with more aggressive dis-
ease may be overrepresented in pilot studies of open-
label treatments.
Previous analyses of data from SLS-I (which
included both cyclophosphamide and placebo groups)
(5) and the study by Goh et al (4) showed that moderate-
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to-severe fibrosis on the baseline HRCT scan is an
independent predictor of response to cyclophosphamide
and poor survival, respectively. The results of our cur-
rent analysis support previous findings that moderate-
to-severe maximum fibrosis on the baseline HRCT
(defined as 50% involvement of fibrosis in the lung
zone with the maximum fibrosis score) is also an inde-
pendent predictor of the decline in the FVC % predicted
(Table 2) (P  0.008). In contrast, baseline ground-glass
opacification and honeycombing were not predictors of
a decline in the FVC % predicted. One of the inclusion
criteria for SLS-I was the presence of any ground-glass
appearance on HRCT scans, with the notion that
ground-glass opacification on HRCT scans represents
reversible inflammation.
Studies on the validity of HRCT for idiopathic
pulmonary fibrosis have been performed. In one study,
the correlation of “ground-glass opacification” on
HRCT with “inflammation” on lung specimens was
weak (r  0.27) (15). In another recent study (16),
normal results of HRCT had a good association with
normal pathology on lung specimens (r  0.72). How-
ever, ground-glass opacification was not associated with
any histologic pattern (r  0.20). It has been suggested
that ground-glass opacification on CT may represent
fine (subresolution) fibrosis rather than reversible in-
flammation (17).
Our results have implications for the design of
future therapeutic trials in SSc-ILD. Cohort enrichment
can be attained by recruiting patients with a moderate-
to-severe degree of baseline fibrosis on HRCT in the
zone(s) with the greatest degree of fibrosis. Our findings
complement those obtained in 215 patients with SSc who
were followed up for 10 years (4), in whom the baseline
FVC % predicted and findings on HRCT scans were
predictive of the mortality risk. Also, based on recent
studies showing a negative association between bron-
choalveolar lavage findings and the FVC % predicted
(4,18), bronchoalveolar lavage–identified cellularity
should likely not be used as an inclusion criterion in
future randomized controlled trials. HRCT is likely to
be included in future SSc-ILD randomized controlled
trials (12,13) for 1) cohort enrichment based on the
extent of disease and 2) adjustment for baseline severity
in key treatment-effect analyses (because it is likely that
a treatment effect may differ in patients with mild rather
than extensive lung disease). In addition, serial HRCT
scans can provide a surrogate end point or more accu-
rate measure of serial change in pulmonary fibrosis.
Moreover, the baseline HRCT is important in excluding
other significant thoracic disease not attributable to SSc
(19).
A major limitation of the current study was that
only 55 of the 77 patients completed the first 12 months
of the trial. However, the present analysis of the natural
history of SSc-ILD is based on the largest sample of
patients with SSc examined to date. Second, this analysis
was restricted to patients participating in a randomized
controlled trial and is not necessarily applicable to
patients in general clinical practice. Third, SSc-ILD trial
designs continue to evolve (19), and the results of this
analysis may not be applicable to other SSc-ILD studies
with different inclusion/exclusion criteria. Last, our ana-
lysis was limited to a 1-year duration. However, current
recommendations (19) propose a trial design with a
minimum of 1 year; our 1-year data may inform the
design of future trials.
In conclusion, we describe the natural course of
SSc-ILD over a period of 1 year. Future SSc-ILD clinical
trials can achieve cohort enrichment by enrolling pa-
tients with HRCT-defined moderate-to-severe fibrosis.
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